Kornimate/medical-research-clean huggingface dataset:
internet-delivered cognitive behaviour therapy for older adults with anxiety

Conditions: Anxiety; Depression

Summary: the purpose of this study is to determine whether tailored internet-administrated cognitive behaviour therapy (icbt) is a feasible approach in the treatment of anxiety symptoms and comorbid depressive symptoms in older adults.


Eligibility criteria:
inclusion criteria: * have anxiety symptoms exclusion criteria: * suicidal ideation * alcohol addiction * other major primary psychiatric disorder * ongoing psychological treatment
cytokine induced killer cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation

Conditions: Multiple Myeloma; Blood and Marrow Transplant (BMT)

Summary: the purpose of the study is to determine if the use of activated t cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing gvhd.


Eligibility criteria:
inclusion criteria:- evidence of recurrent or persistent hematologic malignancy following hla matched allogeneic hematopoietic cell transplant * eligible for dli * no evidence of gvhd * stable immunosuppressive regimen * adequate renal and liver function exclusion criteria:- cml patients who have not received dli, active infections
goal-directed fluid therapy in patients undergoing lower limb surgeries

Conditions: Anesthesia; ERAS; Fluid Overload; Hypovolemia; Surgical Shock

Summary: controlling the amount of fluids given to patients in perioperative setting can significantly influence their outcomes.

to overcome these problems and avoid the complications of over or underhydration, we use the goal-directed fluid therapy(gdft) guided by inferior vena cava(ivc) collapsibility index approach in which dynamic parameters of volume responsiveness as a guide for fluid therapy. this will ensure that the fluids given were deficient from the circulation and improve the recovery of the patients according to enhanced recovery after surgery(eras) protocols.

Eligibility criteria:
inclusion criteria: * patient's acceptance. * patients planned for elective lower limb surgery under spinal anesthesia. * both sexes * body mass index(bmi): \<35 * age: 21 \~ 65 years * american society of anesthesiologists(asa) physical status classification system: class i \& ii * duration of surgery 2\~3 hours exclusion criteria: * advanced kidney, liver, respiratory or cardiovascular disease. * contraindication for spinal anesthesia. * patients shifted to general anesthesia for any reason.
a study of colesevelam for lenalidomide-associated diarrhea

Conditions: Multiple Myeloma; Diarrhea

Summary: the purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.


Eligibility criteria:
inclusion criteria: * memorial sloan kettering cancer center (msk) confirmed diagnosis of multiple myeloma * treatment with single agent lenalidomide maintenance * patient must be \>/= 18 years of age at the time of informed consent * experiencing grade 1 or more diarrhea according to the ctcae 5.0 criteria for at least 4 out of 7 days preceding screening and study inclusion * scheduled to receive lenalidomide maintenance cyles at msk * willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures exclusion criteria: * patients with history of bowel obstruction * patients with serum triglyceride levels \>300 mg/dl * patients wit history of hypertriglyceridemia-induced panreatitis * patients with known hypersensitivity to colesevelam or any component to the formulation * patients currently already receiving a bile acid sequestrant or have previously used bile acid sequestrant drugs for diarrhea and had no benefit * patients with diarrhea secondary to infection. stool studies for gi pathogens should be collected prior to starting colesevelam but do not need to be resulted prior to starting day 1 dose of colesevelam, unless infection is suspected by the treating investigator, in which case (clostridium difficile pcr when clinically indicated, gi pathogen panel, stool ova and parasites, giardia and cryptosporum stool antigen tests will need to be resulted at investigator discretion.)

Keywords: lenalidomide associated diarrhea colesevelam 18-421 memorial sloan kettering cancer center
resistance versus aerobic exercises on breast cancer patients

Conditions: Breast Cancer

Summary: the purpose of the study is to evaluate which is more effective resistance or aerobic exercises on cancer related fatigue and immunity in breast cancer patients undergoing adjuvant chemotherapy.

the problem of cancer related fatigue and decreased immunity, as a result of treatment with adjuvant chemotherapy in breast cancer patients is not well known. fatigue and decreased immunity have a negative impact on work, social relationships, mood, and daily activities and cause significant impairment in overall quality of life, furthermore the need of this study is developed from the lack of information in the published studies about the effect of the treatment with chemotherapy among breast cancer patients on inducing fatigue and decreasing immunity and the effect of resistance and aerobic exercises on improving these changes.

Eligibility criteria:
inclusion criteria: - the subject selection will be according to the following criteria: 1. age range from 30-60 years. 2. females post mastectomy only will participate in the study. 3. all patients undergoing adjuvant chemotherapy and have cancer related fatigue and decreased immunity. 4. all patients enrolled to the study will have their informed consent. exclusion criteria: * the potential participants will be excluded if they meet one of the following criteria: 1. age more than 60 years or less than 30 years. 2. another concurrent malignant disease. 3. subjects suffering from any condition for which resistance or aerobic exercises contraindicated as metastasis, sever osteoporosis and cardiac diseases.
risk stratification using pet in hcm

Conditions: Hypertrophic Cardiomyopathy

Summary: the overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (hcm). the novel approach of this study is to correlate positron emission tomography (pet) findings to ventricular arrhythmias detected by the implantable cardioverter defibrillator (icd). this could potentially lead to an improved risk stratification of hcm patients.

positron emission tomography (pet) is a functional imaging technique that utilizes radioactive tracers to gain information on physiological or pathophysiological processes in vivo. different tracers can provide information on different processes of interest. in cardiology, metabolic processes consuming oxygen (aerobic) can be studied with 11-carbon-acetate, sympathetic innervation can be studied with 11-carbon-hydroxyephedrine and using 15-oxygen-water the myocardial blood flow. structural information of the heart such as left ventricular mass, left ventricular volumes and wall thickness can also be calculated with pet. the aim is to correlate pet parameters and burden of ventricular arrhythmias in order to improve risk stratification in hcm.

Eligibility criteria:
inclusion criteria: * hypertrophic cardiomyopathy, implantable cardioverter defibrillator, informed consent exclusion criteria: * patients younger than 18 years, pregnancy, breast feeding, claustrophobia, intolerance/allergic reaction to adenosin or mannitol, severe hypotension, unstable angina pectoris, incompensated systolic heart failure, increased intracranial pressure, hypovolemia, dipyramidole.

Keywords: hypertrophic cardiomyopathy implantable cardioverter defibrillator positron emission tomography
is family screening improved by genetic testing of familial hypercholesterolemia

Conditions: Hypercholesterolemia, Familial

Summary: to test the hypothesis that in patients with a clinical diagnosis of familial hypercholesterolemia (fh), genetic testing and identification of a causative mutation might enhance the success of family-based cascade screening.

to examine the impact of genetic testing on the efficiency of cascade screening for fh, patients with suspected fh or a clinical diagnosis of fh have been randomized to genetic testing or standard of care with lipid testing alone. after systematic encouragement of family enrollment, as a primary endpoint, the compared the number of probands with relatives enrolled in each group one year after results were returned to probands. the secondary endpoints examined include the number of relatives enrolled within 52 weeks of the genetic counseling call and the number of relatives diagnosed with fh through the study. exploratory subgroup analyses were conducted stratifying the cohort by randomization/genetic test result. further exploratory analyses compared probands' perceptions about high cholesterol diagnosis at baseline and at 20 weeks from enrollment

Eligibility criteria:
inclusion criteria: * for probands, inclusion criteria are as follows: 1. ldl cholesterol \> 220 mg/dl or a previous clinical diagnosis of fh 2. aged 18 years or older 3. ability to provide informed consent 4. willingness/ability to contact a minimum of 2 biological relatives about the study exclusion criteria: * for family members of probands, inclusion criteria are as follows: 1. willingness to participate in the study 2. age 10 or older 3. ability to give informed consent/assent

Keywords: familial hypercholesterolemia genetics cascade screening
employment-based reinforcement to motivate drug abstinence in the treatment of drug addiction. - 2

Conditions: Behavior, Addictive; Cocaine Abuse; Cocaine Dependence; Heroin Dependence; Opioid Dependence

Summary: the purpose of this study is to determine whether long-term exposure to the therapeutic workplace intervention could sustain drug abstinence over an extended period of time in heroin- and cocaine-dependent, unemployed, treatment-resistant young mothers.

the current study is a continuation of the research into the development and evaluation of a novel treatment designed to address the chronic, persistent nature of drug addiction. this treatment, called the therapeutic workplace, integrates abstinence reinforcement contingencies of proven efficacy into a model supported work program. participants were paid to work or to train in the therapeutic workplace but had to provide drug-free urine samples to gain daily access. forty participants were randomly assigned to a therapeutic workplace or usual care control group. therapeutic workplace participants could work for about 5 years. this study reports the effects of the intervention over a follow-up period of 8 years after treatment initiation.

Eligibility criteria:
inclusion criteria: * when originally enrolled in the study, participants were at least 18 years old, unemployed, and methadone maintenance patients of the center for addiction and pregnancy (cap) who continued to use opiates or cocaine during cap treatment. exclusion criteria: * participants were excluded if they were at risk for suicide at the time of intake or if they had serious psychiatric illness (e.g., schizophrenia).

Keywords: behavior therapy cocaine abuse cocaine dependence contingency management heroin dependence methadone opioid dependence
safety and efficacy of acupressure applied through forgtin© in patients with tinnitus

Conditions: Tinnitus, Subjective

Summary: the main objective of this clinical trial is to evaluate the effectiveness and safety of the medical product forgtin with regard to the impairment and change in the sensation of tinnitus (volume, frequency, psychological stress).


Eligibility criteria:
inclusion criteria: * male and female patients (aged \> 18 years) * subjective tinnitus in one or both ears with intermittent or continuous symptoms with a duration of \> 6 months * tinnitus of grade ii, iii or iv according to mini-tinnitus-questionnaire (mini-tf12): * grade ii (score of 8-12): moderately distressed * grade iii (score of 13-18): severely distressed * grade iii (score of 19-24): most severely distressed * if a drug therapy with psychoactive substances (e.g. antidepressants, anticonvulsants) exists at the beginning of the therapeutic intervention, it must have been stable for at least 30 days. the therapy should remain constant during the duration of the study, but a necessary change is not an exclusion criterion. any change in medication is documented in the crf. * provides written informed consent exclusion criteria: * vestibular schwannoma (acoustic neuroma) * objective tinnitus * any other tinnitus-related treatment * ménière's disease * acute infections of the hearing system (acute otitis media, otitis externa, acute sinusitis) * acute infections (acute otitis media, otitis externa, acute sinusitis) * hearing aids or cochlear implants (ci) * any current treatment with anticonvulsants, cortisone, tricyclic antidepressants * other lesions (glomus tumors, meningiomas, adenomas, vascular lesions or neuro-vascular conflicts) detected by clinical assessment * serious, concomitant disorder, including major depression, anxiety * any condition that, in the judgment of the investigator, might prevent safe participation in the study or interfere with study objectives * inability to comply with the protocol requirements
a phase 1 parallel-group, double-blind, placebo-controlled cardiovascular and behavioral study assessing interactions between single doses of oral reserpine and intravenous methamphetamine - 1

Conditions: Amphetamine-Related Disorders

Summary: in this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

in this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Eligibility criteria:
inclusion criteria: * please contact site for more details exclusion criteria: * please contact site for more details
covid-19 seroprevalence in pregnant women and blood donors

Conditions: COVID-19 Respiratory Infection

Summary: the study aims to measure the sars-cov-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of france, and to determine whether these measures are representative of the general population.


Eligibility criteria:
inclusion criteria: * pregnant women * adult female * admitted to hospital for live birth * informed consent * affiliated to the french social security health insurance scheme * blood donors * adult male or female * qualified for whole blood donation (up to 70 years old in france) * informed consent * affiliated to the french social security health insurance scheme exclusion criteria: * legal incapacity or limited legal capacity * subject without health insurance coverage * exclusion period of another study or exclusion period of the french national healthy volunteer registry
a study of mt-0551 in patients with systemic sclerosis

Conditions: Systemic Sclerosis

Summary: the study will verify the superiority of mt-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (ssc) patients using the modified rodnan total skin thickness score (mrtss) as a measure of skin thickening. the safety and pharmacokinetics will also be investigated.


Eligibility criteria:
inclusion criteria: additional screening criteria check may apply for qualification: 1. acr/european league against rheumatism (eular) criteria (2013) systemic sclerosis (ssc) diagnostic criteria satisfied. 2. skin thickening score based on the mrtss between 10 and 22 inclusive. exclusion criteria: additional screening criteria check may apply for qualification: 1. pulmonary hypertension associated with ssc. 2. presence of a serious, ssc-related concurrent illness other than interstitial pneumonia. 3. finding of inadequate respiratory reserve capacity. 4. past history of rituximab, blinatumomab, obinutuzumab, or ofatumumab. 5. presence of a clinically significant active infection requiring antimicrobial therapy. 6. a past history of cancer. 7. past history of a recurrent, clinically significant infection. 8. past history of severe allergy or anaphylactic reaction to a biologic drug product. 9. treatment with live vaccine within a certain period (inactivated vaccine is acceptable).
study of chiglitazar compare with sitagliptin in type 2 diabetes patients

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to evaluate the efficacy and safety of chiglitazar, compare with sitagliptin.

the efficacy and safety will be compared between chiglitazar and sitagliptin after treatment of 24 weeks.

Eligibility criteria:
inclusion criteria: 1. meet the who diagnostic criteria for type 2 diabetes (published on 1999); 2. hba1c≥ 7.5% and ≤ 10.0% after control of diet and exercises; 3. male and female,age between 18 and 70 years; 4. bmi between 18.5-35kg/m2; 5. willing to be assigned to any treatment arm and sign inform consent. exclusion criteria: 1. type 1 diabetes; 2. treated by oral or injective antidiabetic drug before screening, including insulin and herb; 3. fasting plasma glucose \> 13.3 mmol/l (240 mg/dl); 4. resistant hypertension \[blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least different classes of drugs\]; 5. plasma triglyceride \> 500 mg/dl (5.65 mmol/l); 6. is treating by fibrates; 7. history of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy; 8. had transient ischemic attack,cerebrovascular accident or unstable angina in the past 6 months; 9. history of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; 10. had or is having pancreatic diseases; 11. heart failure (nyha classification stage iii or iv), or left ventricular hypertrophy indicated by ecg; 12. hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase or alanine aminotransferase \> 2.5 fold of the upper limit of the normal range; 13. kidney diseases or serum creatinine exceed the normal range: male \> 133 μmol/l or female \>108 μmol/l; 14. had malignancy in the past 5 years, not including basal cell carcinoma; 15. had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or steroids),beta blockers; 16. have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors; 17. edema with unknown reason; 18. alcohol or drug addiction; 19. had participated other drugs' clinical trials in the 3 months before screening; 20. pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct contraception; 21. any condition that make investigator consider the subject is not suitable to participate the trial.

Keywords: chiglitazar sitagliptin diabetes type 2 diabetes
effectiveness and safety of limbal relaxing incisions for correcting post phacoemulsification high astigmatism

Conditions: Astigmatism; Phacoemulsification

Summary: to compare the effect of limbal relaxing incisions (lris) plus spectacle correction versus spectacle correction alone on subjective and objective improvement in visual function for correcting post phacoemulsification high astigmatism .

astigmatism is one of the commonest refractive errors encountered during our clinical practice. surgically induced astigmatism is the main obstacle to achieve good uncorrected visual acuity following cataract surgery. it is estimated that corneal astigmatism of more than 1.0 diopter (d) is found in up to 40% of patients presenting for cataract surgery, 1.5d or more is present in over 20% and above 2.0d in 10%. astigmatism induces distortion of the image leading to compromise quality of vision. in order to achieve better visual results, the effect of postoperative astigmatism should be minimized, management options for corneal astigmatism include glasses, contact lenses, and surgery such as limbal relaxing incisions (lris), refractive laser surgery, toric lenses or rarely corneal grafting. the lris technique involves the placement of incisions corresponding to the steep meridian, resulting in corneal flattening and the reduction of astigmatic power. lri is a safe and an inexpensive procedure, which is simple for experts to perform. although most of the nomograms recommended that lris technique can correct up to 3 d of astigmatism ,it has been found that it is possible to correct even more than 4 d if the incisions were performed on high degrees of astigmatism.

Eligibility criteria:
inclusion criteria: * conventional phacoemulsification was done at least one month earlier. * clear cornea with corneal astigmatism more than 3.0 d. exclusion criteria: * history of corneal surgeries (e.g., keratoplasty, refractive surgery, and corneal wound repair). * ocular trauma. * other intraocular surgery. * patient with corneal opacities. * thin cornea . * any significant ocular disease causing diminution of vision (e.g., optic atrophy, diabetic retinopathy, and age-related macular degeneration), autoimmune disease, and peripheral corneal disease.
dose-escalating and safety study of cp-461 in patients with chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: the purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of cp-461 in patients with chronic lymphocytic leukemia.


Eligibility criteria:
inclusion criteria: 1. relapsed or refractory chronic lymphocytic leukemia. 2. patients must have either intermediate or high risk chronic lymphocytic leukemia according to the rai staging system. 3. must have failed at least 1 prior chemotherapy regimen (at least 1 of which included fludarabine) for cll. 4. no prior therapy within 4 weeks prior to entering the study. patients must have fully recovered from the acute effects of prior therapy. 5. platelet count = 75,000/mm3 , hemoglobin = 8 gm/dl. 6. expected remaining life span \> or = three months. 7. ecog performance status 0 - 2. 8. 18 years or of legal age. 9. male patients or non-pregnant and non-lactating female patients, who are either using adequate birth control, are surgically sterile or post-menopausal. 10. negative serum pregnancy test, if fertile female. 11. willingness and ability to sign an informed consent document. exclusion criteria: 1. evidence of cns involvement. 2. other active malignancy or history of treatment of any malignancy (excluding non-melanoma skin cancer) within the previous three years. 3. previous therapy with campath. 4. patients with low-risk chronic lymphocytic leukemia according to the rai staging system. 5. concurrent immunotherapy. 6. concurrent use of steroids. 7. use of an investigational medication or device within 1 month of initiating study therapy. 8. patients who have had allogeneic bone marrow transplantation. 9. total serum bilirubin above the upper limit of normal; serum creatinine above the upper limit of normal. 10. ast or alt \> 2.5 times the upper limit of normal. 11. any condition or any medication which may interfere with the conduct of the study.

Keywords: chronic lymphocytic leukemia leukemia cll